Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 526 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

NICE turns down Novartis breast cancer drug

Everolimus is the sixth treatment that NICE has turned down for patients with advanced breast cancer since 20 November 2006. Everolimus is the first new licensed therapeutic drug